Condition
Collagenous Colitis
Total Trials
6
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 6 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
67%
4 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (1)
P 3 (4)
Trial Status
Completed3
Unknown3
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT03658993Phase 3UnknownPrimary
Rifaximin-treatment of Collagenous Colitis
NCT01928667Completed
Case-Control Study to Identify Risk Factors for Microscopic Colitis
NCT01504048Not ApplicableUnknown
Usefulness of Chromoendoscopy in Diagnosing Microscopic Colitis
NCT00450086Phase 3CompletedPrimary
Budesonide Capsules vs. Mesalazine Granules vs. Placebo in Collagenous Colitis
NCT00180076Phase 3CompletedPrimary
Budesonide for Maintenance Treatment of Collagenous Colitis
NCT00139165Phase 3UnknownPrimary
Long-Term Treatment of Collagenous Colitis With Budesonide
Showing all 6 trials